A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

PHASE3CompletedINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Actinic Keratoses
Interventions
DRUG

PEP005 (ingenol mebutate) Gel

two day treatment

DRUG

Vehicle gel

two day treatment

Trial Locations (20)

4217

The Skin Centre, Benowa

6100

Burswood Dermatology, Victoria Park

14623

Dermatology Associates of Rochester, Rochester

30263

Medaphase Inc, Newnan

32073

Park Avenue Dermatology, Orange Park

32174

Advanced Dermatology & Cosmetic Surgery, Ormond Beach

34741

Advanced Dermatology and Cosmetic Research, Kissimmee

37072

Rivergate Dermatology and Skin Care Center, Goodlettsville

38138

Dermatology East, Germantown

44121

University Hospitals Case Medical Center, Cleveland

46168

Dermatology Center of Indiana/Indiana Clinical Trials Center, Plainfield

48202

Henry Ford Health Systems, Detroit

77845

J & S Studies, Inc., College Station

80210

Colorado Medical Research Center, Denver

85206

Omni Dermatology Research, Mesa

87106

Academic Dermatology Associates, Albuquerque

97223

Oregon Medical Research, Portland

30078-3250

Gwinnett Clinical Research Centre, Snellville

08075

Karen S. Harkaway, MD. LLC, South Delran

97239-4501

Oregon Health and Science University, Portland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Peplin

INDUSTRY

NCT00742391 - A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations | Biotech Hunter | Biotech Hunter